ProMIS Neurosciences Plunges 26% on Reverse Stock Split: A Desperate Bid to Stay Listed?

Summary
• ProMIS Neurosciences (PMN) slumps 26.24% intraday to $0.3098, its 52-week low of $0.30.
• A 1-for-25 reverse stock split announced November 24 triggers immediate selloff amid Nasdaq delisting threats.
• Q3 results reveal a $0.24/share loss, missing estimates by 59%, compounding investor skepticism.

ProMIS Neurosciences is in freefall, trading at its lowest level since 2023 amid a dramatic reverse stock split and deteriorating fundamentals. The biotech firm’s shares have cratered 26.24% in a single session, driven by a desperate bid to comply with Nasdaq’s $1.00 minimum bid price rule. With the stock now teetering at its 52-week low, the company’s survival hinges on whether the split can stabilize its valuation before December 29’s compliance deadline.

Reverse Stock Split Triggers Sharp Selloff as PMN Fights Nasdaq Delisting
The 1-for-25 reverse stock split, effective November 28, is a last-ditch effort to avert delisting after repeated failures to meet Nasdaq’s $1.00 bid price threshold. While the move reduces the number of outstanding shares from 53.8 million to 2.15 million, it has sparked immediate panic selling. Investors are reacting to the company’s dire financials: a Q3 loss of $0.24/share (vs. $0.15 expected) and a cash burn rate that has eroded market confidence. The split’s psychological impact—reducing the share price to near-pennies—has amplified perceptions of weakness, triggering a liquidity crunch as traders exit positions.

Technical Deterioration and Liquidity Risks: A Bearish Playbook
• 200-day average: $0.5700 (well below current price)
• RSI: 51.83 (neutral but trending lower)
• MACD: -0.0148 (bearish crossover with signal line at -0.0184)
• Bollinger Bands: Price at lower band ($0.3557), signaling oversold conditions

ProMIS is trapped in a death spiral. The RSI’s neutral reading masks the stock’s structural collapse, with the 200-day SMA acting as a distant, unattainable target. The MACD’s bearish divergence confirms deteriorating momentum. Key levels to watch: the 52-week low at $0.30 and the 20-day SMA of $0.4029. With no options liquidity and a 14.3% turnover rate, aggressive short-term traders should avoid further exposure. The lack of leveraged ETFs compounds the risk of a liquidity vacuum post-split.

Backtest ProMIS Neurosciences Stock Performance
Here is the back-test report for “PMN −26 % Intraday Plunge Rebound” compiled from 2022-01-01 through 2025-11-24.Explanation of auto-selected parameters 1. Stop-loss 15 %, take-profit 30 %, max 20 holding days: conservative yet practical settings often used for high-volatility micro-cap biotech names like PMN. 2. Price type “close”: standard for evaluating position exits relative to the stop/take thresholds. 3. Date range 2022-01-01 to now: spans the entire period requested by the user.Feel free to open the interactive module above to view detailed equity curve, P&L statistics, and trade log.

A Crucible for PMN: Survival or Collapse by December?
ProMIS’s survival hinges on its ability to maintain a post-split share price above $1.00 through December 29. The technical indicators—particularly the MACD and Bollinger Bands—suggest a continuation of the downtrend unless a catalyst emerges. Biogen (BIIB), the sector leader, rose 0.39% today, highlighting the biotech sector’s mixed signals. Investors must monitor the split’s execution and Nasdaq’s compliance rulings. For now, the message is clear: PMN is a high-risk, high-reward proposition with no margin for error. Watch for a breakdown below $0.30 or a Nasdaq intervention.